[{"id":"a3d44513-3d22-4617-a3e3-b78c69f0ade8","acronym":"SGNB7H4V-001","url":"https://clinicaltrials.gov/study/NCT05194072","created_at":"2022-01-18T12:54:03.783Z","updated_at":"2024-07-02T16:34:27.305Z","phase":"Phase 1","brief_title":"A Study of SGN-B7H4V in Advanced Solid Tumors","source_id_and_acronym":"NCT05194072 - SGNB7H4V-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e felmetatug vedotin (PF-08046048)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-11"}]